CVN424   Click here for help

GtoPdb Ligand ID: 11514

Synonyms: compound 6i [PMID: 33861086] | CVN-424
Compound class: Synthetic organic
Comment: CVN424 is a first-in-class, clinical stage, nondopaminergic inverse agonist of GPR6. It is orally bioavailable, and can penetrate the CNS [1,3]. In in vivo Parkinson's disease models, inhibiting GPR6 activity with CVN424 normalises both activity in basal ganglia circuitry and motor behaviour.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 79.82
Molecular weight 473.22
XLogP 3.1
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(c(c1)F)OC1CCN(CC1)c1nc2CCN(Cc2nc1N[C@H]1COCC1)C(=O)C
Isomeric SMILES Fc1ccc(c(c1)F)OC1CCN(CC1)c1nc2CCN(Cc2nc1N[C@H]1COCC1)C(=O)C
InChI InChI=1S/C24H29F2N5O3/c1-15(32)31-10-6-20-21(13-31)28-23(27-17-7-11-33-14-17)24(29-20)30-8-4-18(5-9-30)34-22-3-2-16(25)12-19(22)26/h2-3,12,17-18H,4-11,13-14H2,1H3,(H,27,28)/t17-/m1/s1
InChI Key HSWVJQBEXRKOBZ-QGZVFWFLSA-N
No information available.
Summary of Clinical Use Click here for help
CVN424 has progressed to clinical evaluation for efficacy in Parkinson's disease. Phase 1 first-in-human results (safety, tolerability, and pharmacokinetics) were published in April 2022 [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04191577 Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations Phase 2 Interventional Cerevance Beta, Inc.
NCT03657030 Study of CVN424 in Healthy Subjects Phase 1 Interventional Cerevance Beta, Inc. 2